Cerebras Systems, an AI chipmaker, reported its first earnings since going public in May, showing a 92% revenue increase to $193.4 million in Q1 compared to last year. Despite the strong revenue growth and a reduced net loss of $14 million, the stock dropped 7% in after-hours trading and has fallen 28% since its IPO peak. The company expects continued strong growth with Q2 revenue forecasted to rise 88% year-over-year and full-year revenue projected between $855.5 million and $865 million. Cerebras aims to compete with Nvidia by offering chips with higher memory capacity and has secured major deals with Amazon Web Services and OpenAI.
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
